KMD Bioscience’s antibody platform is a comprehensive service system covering the entire process from antigen design to antibody application. Leveraging a variety of core technologies—including hybridoma technology, phage/yeast display technology, and cellular immunology—the platform provides clients with customized development services for monoclonal antibodies, polyclonal antibodies, and recombinant monoclonal antibodies. The service process begins with client project consultation and proposal confirmation, followed by antigen design and synthesis (covering various types such as small molecules, peptides, and proteins). This is followed by animal immunization (supporting multiple species including mice, rabbits, sheep, and llamas) or in vitro antibody library construction and screening, ultimately leading to antibody purification, sequencing, affinity maturation, and functional validation. Leveraging standardized animal facilities and a rigorous quality control system, the platform delivers highly specific, high-affinity antibody products and provides extensive support for downstream applications such as ELISA, Western blotting (WB), immunohistochemistry (IHC), and flow cytometry.